[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353537-105":59,"doc-detail-353537-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","extrachromosomal-microdna-signature-as-a-candidate-biomarker-in-pediatric-acute-lymphoblastic-leukemia","Extrachromosomal microDNA Signature as a Candidate Biomarker in Pediatric Acute Lymphoblastic Leukemia","","Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, yet refractory and relapsed disease still causes leading cancer mortality. Accessible, minimally invasive biomarkers are needed for frequent monitoring and timely intervention. This study examines microDNA, a novel extrachromosomal DNA enriched from highly transcribed and/or accessible genomic regions, and tests whether microDNA-producing gene repertoires change with disease stage. MicroDNA profiling of paired bone marrow and plasma samples identifies plasma-detectable gene panels linked to active disease, with a 11-gene signature persisting from diagnosis through relapse but disappearing in remission.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/extrachromosomal-microdna-signature-as-a-candidate-biomarker-in-pediatric-acute-lymphoblastic-leukemia/353537/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/extrachromosomal-microdna-signature-as-a-candidate-biomarker-in-pediatric-acute-lymphoblastic-leukemia/353537.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are biomarkers needed in pediatric acute lymphoblastic leukemia (ALL)?","Question",{"text":113,"@type":114},"Despite improved therapies, refractory and relapsed ALL remains a major cause of childhood cancer mortality. The study emphasizes the need for accessible, minimally invasive biomarkers that can be repeatedly sampled and reflect disease status for prompt intervention.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What is microDNA and why might it serve as a biomarker?",{"text":118,"@type":114},"MicroDNA is a small extrachromosomal DNA class that preferentially originates from gene segments with high transcriptional activity and/or increased chromatin accessibility. Its nonrandom genomic origins suggest it reflects cellular and gene expression states relevant to cancer progression.",{"name":120,"@type":111,"acceptedAnswer":121},"What microDNA signature was identified across disease stages?",{"text":122,"@type":114},"Analyses found microDNA gene panels associated with active disease. A signature comprising 11 microDNA-producing genes was detected in plasma at diagnosis and overrepresented in patients who relapsed, with microDNA from the same genes confirmed in relapse plasma while disappearing in remission.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},353537,1790219218,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-25-0419](https://doi.org/10.1158/2767-9764.CRC-25-0419)  OPEN ACCESS  \nExtrachromosomal microDNA Signature as a Candidate Biomarker in Pediatric Acute Lymphoblastic Leukemia  \nIvan Brukner1, Vincent Gagn2, Alex Richard-St-Hilaire2, Pascal Tremblay-Dauphinais2, Claire Fuchs2, Henrique Bittencourt2,3, Teodor Veres4, Daniel Sinnett2,3, and Maja Krajinovic2,3,5  \n􀀶  \nABSTRACT  \nAcute lymphoblastic leukemia (ALL) is the most common childhood cancer. Despite improved therapies, refractory and relapsed ALL remain the leading cause of cancer-related mortality in children. There is a need for accessible biomarkers for frequent, minimally invasive disease monitoring and prompt intervention. MicroDNA is a novel extrachromosomal DNA that preferentially originates from gene segments with high transcriptional activity and/or increased chromatin accessibility. We investigated whether microDNA-producing genes repertoire changes in a disease-dependent manner. We characterized microDNAs in 52 paired bone marrow (BM) and plasma samples from pediatric patients with ALL at diagnosis, relapse, and remission. No difference in the length or number of microDNA was noted across stages, but comparative analysis of microDNA profiles led to the identification of microDNA gene panels associated with active disease. The relative distribution of these genes was significantly different from that expected by chance (P \u003C 0.0001) . Analyses of BM samples identified a signature comprising 289 distinct microDNA-producing genes present in multiple patients at diagnosis  \nand relapse but absent in remission. The best biomarker candidates were 11 microDNA-producing genes identified also in plasma samples at diagnosis and overrepresented in patients who relapsed (P ¼ 0.006) . MicroDNA from the same genes was confirmed in relapse plasma samples. All signature genes are known to be involved in cancer proliferation or drug response. MicroDNA seems to be a candidate for a novel class of biomarkers for ALL, with the potential to improve precision diagnostics, particularly through their identification in plasma samples. Further validation in an independent cohort of patients is warranted.  \nSignificance: Despite high cure rates, 10% to 15% of pediatric patients with ALL experience relapse. We identified a plasma-detectable microDNA signature from 11 genes that persists from diagnosis through relapse but disappears in remission. These findings demonstrate the potential of microDNA profiles as prognostic biomarkers in pediatric ALL, enabling noninvasive monitoring of disease status and risk stratification.  \nIntroduction  \nAcute lymphoblastic leukemia (ALL) is the most common childhood malignancy. Although cure rates have improved dramatically, 10% to 15% of patients still experience relapse during or after therapy and have poor prognosis ( 1, 2) . Bone marrow (BM) biopsy is the gold standard for the  \n1Lady Davis Institute for Medical Research, McGill University, Montreal, Canada. 2CHU Sainte-Justine Research Center Azrieli, Charles-Bruneau Cancer Center, University of Montreal, Montreal, Canada. 3Department of Pediatrics, Faculty of Medicine, University of Montreal, Montreal, Canada. 4National Research Council Canada, Boucherville, Canada. 5Department of Pharmacology and Physiology, Faculty of Medicine, University of Montreal, Montreal, Canada.  \nCorresponding Author: Maja Krajinovic, Department of Pediatrics, Faculty of Medicine, University of Montreal, 3175 chemin de la Cte-Ste-Catherine, Montreal H3T1C5, [Canada. E-mail:](Canada. E-mail: maja.krajinovic@umontreal.ca)[ maja.krajinovic@umontreal.ca](Canada. E-mail: maja.krajinovic@umontreal.ca)  \n[doi:](doi: 10.1158/2767-9764)[ 10.1158/2767-9764](doi: 10.1158/2767-9764) .CRC-25-0419  \nThis open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.  \n©2025 The Authors; Published by the American Association for Canc","cbCaidjcqPKOKxON","https://ap.wps.com/l/cbCaidjcqPKOKxON","pdf",2174158,"English","# Abstract\n# Significance\n# Introduction","[{\"question\":\"Why are biomarkers needed in pediatric acute lymphoblastic leukemia (ALL)?\",\"answer\":\"Despite improved therapies, refractory and relapsed ALL remains a major cause of childhood cancer mortality. The study emphasizes the need for accessible, minimally invasive biomarkers that can be repeatedly sampled and reflect disease status for prompt intervention.\"},{\"question\":\"What is microDNA and why might it serve as a biomarker?\",\"answer\":\"MicroDNA is a small extrachromosomal DNA class that preferentially originates from gene segments with high transcriptional activity and/or increased chromatin accessibility. Its nonrandom genomic origins suggest it reflects cellular and gene expression states relevant to cancer progression.\"},{\"question\":\"What microDNA signature was identified across disease stages?\",\"answer\":\"Analyses found microDNA gene panels associated with active disease. A signature comprising 11 microDNA-producing genes was detected in plasma at diagnosis and overrepresented in patients who relapsed, with microDNA from the same genes confirmed in relapse plasma while disappearing in remission.\"}]","Extrachromosomal microDNA Signature as a Candidate Biomarker in Pediatric Acute Lymphoblastic Leukemia | PDF",1790105951,23,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f737bbcea109ea8fc316bd0db7f77415.webp",983,1263,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4a2dee61af190377170b48ccf24f2b76.webp",982,1262,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fec84e709801272fa46c77b85813fc7e.webp",981,1261,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5752663fb03f2f9392fec5fc742d729.webp",980,1259]